Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
GnRH-a-1M
The First People's Hospital of Lianyungang
Adenomyosis of Uterus
1 trial -
GnRHa
The First People's Hospital of Lianyungang
Cesarean Scar Diverticula
1 trial -
Goserelin
The First People's Hospital of Lianyungang
Allogeneic Haematopoietic Stem Cell Transplantation
1 trial -
Group A
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Crohn Disease
1 trial -
Group A (clinical guideline+machine learning)
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Hypertension
1 trial -
Group S: sugammadex injection
Hospital Authority, Hong Kong
Head and Neck Surgery
1 trial -
Guideline-directed medical therapy
The First People's Hospital of Lianyungang
Heart Failure With Reduced Ejection Fraction
1 trial -
HCQ/CQ and CAB combined treatment
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Resistance, Disease
1 trial -
HG204
The First People's Hospital of Lianyungang
MECP2 Duplication Syndrome
1 trial -
HPV Self-Collection
Hospital Authority, Hong Kong
Cervical Cancers
1 trial -
Health education and conservative management of clinical routines
The First People's Hospital of Lianyungang
Recurrent Acute Pancreatitis
1 trial -
HellenCare
The First People's Hospital of Lianyungang
Alzheimer's Disease Dementia
1 trial -
Heparin Sodium
The First People's Hospital of Lianyungang
Cerebral Aneurysm
1 trial -
Hetrombopag
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Hematological Disease
1 trial -
High Dose GGQL Decoction
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Diabetes Mellitus, Type 2
1 trial -
High risk experimental group
The First People's Hospital of Lianyungang
Adolescent Idiopathic Scoliosis
1 trial -
High-dose vitamin D2 softgels
The First People's Hospital of Lianyungang
Chronic Kidney Disease 5D
1 trial -
Hippocampal avoidance WBRT
Hospital Authority, Hong Kong
Metastatic Malignant Neoplasm to Brain
1 trial -
House dust mite
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Allergic Asthma
1 trial -
Huang-long Zhi-xiao Granule
The First People's Hospital of Lianyungang
Asthma Chronic
1 trial -
Huangjing Yangji Formula Granules
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Sarcopenia
1 trial -
Huangqi Guizhi Wuwu decoction
The First People's Hospital of Lianyungang
Diabetic Nephropathies
1 trial -
Human Urinary Kallidinogenase
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Acute Ischemic Stroke
1 trial -
Human umbilical cord mesenchymal stem cells
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Knee Osteoarthritis
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources